The ovarian cancer-derived secretory/releasing proteome: A repertoire of tumor markers

• Published in: Proteomics (Weinheim) 2012-06, Vol.12 (11), p.1883-1891
• Main Authors: Zhang, Ying, Xu, Bin, Liu, Yu, Yao, Hongwen, Lu, Nenan, Li, Bin, Gao, Jia, Guo, Suping, Han, Naijun, Qi, Jun, Zhang, Kaitai, Cheng, Shujun, Wang, Hongxia, Zhang, Xuemin, Xiao, Ting, Wu, Lingying, Gao, Yanning
• Format: Article
• Language: English
• Subjects: Analytical, structural and metabolic biochemistry; Biological and medical sciences; Biomarker; Biomarkers; Biomarkers, Tumor - analysis; Biomarkers, Tumor - blood; Biomedicine; Blood; Cells, Cultured; Culture Media, Conditioned; Data processing; Databases, Protein; Female; Female genital diseases; Fundamental and applied biological sciences. Psychology; Gynecology. Andrology. Obstetrics; Humans; Malignancy; Medical sciences; Membrane Glycoproteins - analysis; Membrane Glycoproteins - blood; Membrane proteins; Membrane Proteins - analysis; Miscellaneous; Neoplasm Proteins - analysis; Neoplasm Proteins - blood; Organ culture; Ovarian cancer; Ovarian Neoplasms - diagnosis; Ovarian Neoplasms - metabolism; Plasma; Plasma membranes; Proteins; Proteome - analysis; Proteomics; Secretome; Tandem Mass Spectrometry; Therapeutic applications; Tissue inhibitor of metalloproteinase 2; Tissue Inhibitor of Metalloproteinase-2 - analysis; Tissue Inhibitor of Metalloproteinase-2 - blood; Trypsin; Tumor markers; Tumors; Versicans - analysis; Versicans - blood
• ISSN: 1615-9853; 1862-8346; 1615-9861
• DOI: 10.1002/pmic.201100654

Ovarian cancer is the most lethal gynecological malignancy worldwide, and early detection of this disease using serum or plasma biomarkers may improve its clinical outcome. In the present study, a large scale protein database derived from ovarian cancer was created to enable tumor marker discovery. First, primary organ cultures were established with the tumor tissues and corresponding normal tissues obtained from six ovarian cancer patients, and the serum‐free conditioned medium (CM) samples were collected for proteomic analysis. The total proteins from the CM sample were separated by SDS‐PAGE, digested with trypsin and then analyzed by LC‐MS/MS. Combining data from the tumor tissues and the normal tissues, 1129 proteins were identified in total, of which those categorized as “extracellular proteins” and “plasma membrane proteins” accounted for 21.4% and 16.9%, respectively. For validation, three secretory proteins (NID1, TIMP2, and VCAN) involved in “organ development”‐associated subnetwork, showed significant differences between their levels in the circulating plasma samples from ovarian cancer patients and healthy women. In conclusion, this ovarian cancer‐derived protein database provides a credible repertoire of potential biomarkers in blood for this malignant disease, and deserves mining further.